Supergen Inc. About
Supergen Inc SuperGen is a pharmaceutical company dedicated to
the development and commercialization of therapies for solid tumors, hematological
malignancies and blood disorders. SuperGen currently has three anti-cancer
drugs approved for use, another three either already in Phase III trials or soon
expected to be entering Phase III trials, and a broad portfolio of other cancer
drugs in various stages of development. Nipent® is a chemotherapy agent currently indicated
for the treatment of hairy cell leukemia. Multiple clinical trials are currently
ongoing for other disease states --(bone marrow transplant patients with acute
Graft-Vs.-Host Disease) Mitomycin is SuperGen's generic brand of
the chemotherapy agent Mutamycin®. Orathecin --Orathecin (rubitecan)
is an orally active camptothecin; a topoisomerase I inhibitor that was developed
for the treatment of pancreatic cancer. Avicine -- colorectal
cancer More About Supergen